9 Facts About Lichen Sclerosus and Menopause That Gynecologists Underdiagnose
The number of women who describe years of itching, tearing, and painful sex — only to be handed a tube of lubricant and sent home — is genuinely heartbreaking. Lichen sclerosus leaves real, visible changes to the vulva, and those changes are reversible when caught early. If something feels wrong down there and the answers aren't adding up, this page exists because you deserve a better explanation.
Learn more about Rose →Lichen Sclerosus Is a Distinct Inflammatory Skin Condition, Not a Dryness Problem
Lichen sclerosus (LS) is a chronic, immune-mediated dermatosis that causes inflammation, thinning, and architectural changes to the vulvar skin — it is not simply low moisture or estrogen loss. The tissue becomes white, fragile, and prone to tearing, fissuring, and scarring over time. Understanding this distinction matters enormously, because the treatment pathway is completely different from that of genitourinary syndrome of menopause (GSM).
Estrogen Decline at Menopause Does Not Cause LS — But It Creates the Conditions for It to Flare
The exact cause of lichen sclerosus is not fully understood, but it is considered autoimmune in origin, with genetic, hormonal, and local tissue factors all playing a role. Falling estrogen at perimenopause thins and dries vulvar tissue, which appears to lower the threshold for LS to emerge or worsen in women who carry an underlying predisposition. This is why LS clusters so strongly around menopause — not because menopause causes it, but because the hormonal environment makes vulnerable tissue less resilient.
The Classic Symptoms Are Routinely Attributed to Something Else Entirely
Intense vulvar itching (particularly at night), skin that appears pale or white, painful sex, tearing with minimal friction, and a burning sensation are the hallmark symptoms of LS — and all of them are regularly misattributed to thrush, contact dermatitis, or plain vaginal dryness. Studies suggest average diagnostic delay can exceed five years from symptom onset to confirmed diagnosis. Women are frequently offered antifungal creams for a condition that will not respond to them.
A Visual Inspection Alone Is Not Enough — Diagnosis Should Be Confirmed by Biopsy
While experienced dermatologists and vulvar specialists can often recognise LS by its characteristic appearance — white, parchment-like skin, loss of the labia minora architecture, clitoral hood fusion — the definitive diagnosis requires a skin biopsy. Biopsy is particularly important because LS shares visual overlap with other vulvar dermatoses, and because a small but real lifetime risk of vulvar squamous cell carcinoma (estimated at 3–5%) makes accurate diagnosis and long-term monitoring essential. Women who have only ever had a brief visual check during a smear test have not been adequately assessed.
Ultra-Potent Topical Corticosteroids Are the First-Line Treatment — Not Hormones
Clobetasol propionate 0.05% ointment, an ultra-potent topical corticosteroid, is the evidence-backed first-line treatment for lichen sclerosus and has been shown to reduce symptoms, halt progression, and in some cases reverse early scarring. This is a fundamentally different treatment to vaginal estrogen, which addresses GSM but does not adequately treat the inflammatory process driving LS. Some women benefit from both treatments simultaneously, but local estrogen cannot substitute for appropriate steroid therapy in LS.
Vaginal Estrogen Can Play a Supportive Role — But Only Alongside Proper LS Treatment
Because many menopausal women have both lichen sclerosus and genitourinary syndrome of menopause simultaneously, vaginal estrogen is often a valuable adjunct — it restores moisture, improves tissue resilience, and reduces the friction and microtrauma that can aggravate LS flares. However, the evidence is clear that vaginal estrogen does not treat the underlying autoimmune inflammation of LS, and prescribing it as the sole intervention misses the primary pathology. Women with both conditions benefit most from a treatment plan that addresses each one specifically.
Untreated LS Causes Permanent Structural Changes to the Vulva
Left unmanaged, lichen sclerosus progresses to scarring that gradually erases normal vulvar anatomy — the labia minora can fuse and disappear, the clitoral hood may seal over the clitoris (phimosis), and the vaginal opening can narrow significantly, making penetration painful or impossible. These changes are not reversible once established, which is precisely why early diagnosis and consistent treatment matter so much. The window to prevent architectural loss is real, and it is open — but not indefinitely.
There Is a Small but Real Association With Vulvar Cancer — Which Makes Surveillance Non-Negotiable
Women with lichen sclerosus have an estimated 3–5% lifetime risk of developing vulvar squamous cell carcinoma, a risk substantially higher than the general population. Chronic uncontrolled inflammation, persistent itching leading to scratching, and delayed treatment are all thought to amplify that risk. This does not mean LS is a cancer diagnosis — it is not — but it does mean that any woman with confirmed LS should have regular vulvar self-examination and annual review with a clinician familiar with the condition.
Long-Term Maintenance Therapy Is Usually Necessary — Stopping Treatment Causes Relapse
Many women are given a short course of corticosteroid ointment, experience relief, and then stop — only for symptoms and tissue changes to return within months. Current evidence supports ongoing maintenance therapy using a reduced frequency of application (often once or twice weekly) indefinitely, rather than treating LS like an acute infection that resolves with a fixed course. Regular follow-up with a gynaecologist, dermatologist, or vulvar specialist is the standard of care, and women who understand this are better equipped to advocate for themselves at every appointment.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.